IS ASIA READY FOR BIOSIMILARS? A REVIEW OF THE REGULATORY LANDSCAPE FOR BIOSIMILARS?

被引：0
|
作者：
Duttagupta, S. [1 ]
Park, S. [1 ]
Akandwanaho, D. [1 ]
Jeong, J. J. [1 ]
Feldman, H. [1 ]
机构：
[1] CBPartners, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.430
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP97
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [21] Biosimilars: The US Regulatory Framework
    Christl, Leah A.
    Woodcock, Janet
    Kozlowski, Steven
    ANNUAL REVIEW OF MEDICINE, VOL 68, 2017, 68 : 243 - 254
  • [22] European regulatory guidelines for biosimilars
    Wiecek, Andrzej
    Mikhail, Ashraf
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 17 - 20
  • [23] Regulatory guidelines for biosimilars in Malaysia
    Abas, Arpah
    BIOLOGICALS, 2011, 39 (05) : 339 - 342
  • [24] Regulatory aspects of biosimilars in Europe
    Zuniga, Leyre
    Calvo, Begona
    TRENDS IN BIOTECHNOLOGY, 2009, 27 (07) : 385 - 387
  • [25] Biosimilars: Regulatory and Practical Considerations
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 12 - 15
  • [26] EVOLVING GLOBAL REGULATORY LANDSCAPE FOR APPROVAL OF BIOSIMILARS: A STRUCTURED LITERATURE REVIEW ON CURRENT CHALLENGES AND FUTURE CONSIDERATIONS
    Car, E. S.
    Barbier, L.
    Vulto, A.
    Huys, I
    Simoens, S.
    VALUE IN HEALTH, 2023, 26 (12) : S263 - S264
  • [27] REVIEW OF BIOSIMILARS IN RHEUMATOLOGY
    Rischin, A.
    Ostor, A.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 16 - 16
  • [28] Biosimilars Now Just About Ready to Roll
    Capuano, Vincent L.
    Fitzpatrick, Anthony J.
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (15): : 10 - +
  • [29] The current status of the biosimilars landscape in China
    Xu, Gangling
    Wang, Junzhi
    BIOLOGICALS, 2024, 85
  • [30] Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers, Hans C.
    Schellekens, Huub
    DRUG DISCOVERY TODAY, 2019, 24 (10) : 1963 - 1967
12345